alpha-aminopyridine has been researched along with Malignant Melanoma in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.00) | 29.6817 |
| 2010's | 12 (60.00) | 24.3611 |
| 2020's | 7 (35.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amaria, RN; Ascierto, PA; Berking, C; Berlin, JD; Carlino, MS; De Vos, FYFL; Harney, AS; Johnson, DB; Kim, KB; Postow, MA; Reddy, MB; Schuler, M; Sosman, JA; van Herpen, CML; Zimmer, L | 1 |
| Blackham, A; Box, J; Demberger, L; Federowicz, B; Friedland, JC; Ginn, S; Horton, M; Knoerzer, D; McIntosh, A; Nair, S; Shapiro, M; Sheikh, H; Stuhlmiller, TJ; Wolfe, Z | 1 |
| Moschos, SJ | 1 |
| Ali, LR; Bollenrucher, N; Dougan, M; Dougan, SK; Garrido-Castro, AC; Goel, S; Lenehan, PJ; Shapiro, GI; Stump, CT; Tolaney, SM | 1 |
| Aasen, SN; Bjerkvig, R; Feng, Z; Hoang, T; Knappskog, S; Parajuli, H; Roy, K; Stokke, K; Thorsen, F; Wang, J | 1 |
| Aplin, AE; Chervoneva, I; Erkes, DA; Field, CO; Rosenbaum, SR; Villanueva, J | 1 |
| Chai, J; Li, M; Li, Z; Liu, X; Mi, J; Qin, H; Wu, J; Xu, J | 1 |
| Meissner, M; Möller, M; Möser, CV; Niederberger, E; Schiffmann, S; Schmetzer, J; Wasel, J; Weigert, A; Weiß, U | 1 |
| Aptullahoglu, E; Esfandiari, A; Ho, YH; Lovat, P; Lunec, J; Mahdi, AK; Wang, N; Wu, CE | 1 |
| Luo, Q; Qian, Y; Qiao, S; Xu, G; Zhang, Z | 1 |
| Algazi, AP; Daud, A; Munster, PN; Ortiz-Urda, S; Pelayo, A; Posch, C; Rotow, J | 1 |
| Blank, C; Cornelissen-Steijger, PD; Geukes Foppen, MH; Goding, CR; Graeber, TG; Haanen, J; Hugo, W; Kemper, K; Kong, X; Krijgsman, O; Lo, RS; McDermott, U; Müller, J; Peeper, DS; Possik, PA; Ribas, A; Robert, L; Song, C; Tsoi, J | 1 |
| Miele, L; Morello, S; Pinto, A; Porta, A; Sorrentino, C | 1 |
| Konecny, GE | 1 |
| Amaria, R; Bassett, RL; Bernatchez, C; Bosenberg, MW; Cascone, T; Chen, G; Chen, JQ; Chen, PL; Cooper, ZA; Creasy, C; Davies, MA; Deng, W; Forget, MA; Gajewski, TF; Gershenwald, JE; Glitza, IC; Haymaker, C; Heffernan, TP; Hu, J; Hwu, P; Kwong, LN; Lazar, AJ; Li, HS; Liang, X; Liu, C; Lizée, G; Malu, S; Mbofung, R; McKenzie, JA; McQuade, JL; Overwijk, WW; Peng, W; Radvanyi, L; Roszik, J; Spranger, S; Tetzlaff, MT; Tieu, TN; Torres-Cabala, CA; Wargo, JA; Williams, LJ; Woodman, SE; Xu, C; Yu, X; Zhang, C | 1 |
| Geisslinger, G; King-Himmelreich, TS; Laarmann, K; Meissner, M; Möser, CV; Niederberger, E; Olbrich, K; Wolters, MC | 1 |
| Beckmann, RP; Burke, TF; Cronier, DM; Hartman, D; Kulanthaivel, P; Tate, SC | 1 |
| Holy, J; Kolomitsyna, O; Krasutsky, D; Krasutsky, PA; Oliveira, PJ; Perkins, E | 1 |
| Basak, G; Czajkowski, K; Dziembowska, M; Górska, A; Gołab, J; Grzela, T; Jalili, A; Kamińska, B; Kasprzycka, M; Kazimierczuk, Z; Lasek, W; Maj, M; Mikłaszewicz, P; Młynarczuk, I; Nowaczyk, M; Nowis, D; Sieńko, J; Switaj, T | 1 |
1 review(s) available for alpha-aminopyridine and Malignant Melanoma
| Article | Year |
|---|---|
Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Topics: Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Liposarcoma; Lymphoma, Mantle-Cell; Melanoma; Neoplasms, Germ Cell and Embryonal; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Signal Transduction | 2016 |
19 other study(ies) available for alpha-aminopyridine and Malignant Melanoma
| Article | Year |
|---|---|
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma.
Topics: Aminopyridines; Benzimidazoles; GTP Phosphohydrolases; Humans; Melanoma; Membrane Proteins; Purines | 2022 |
Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma.
Topics: Aminopyridines; Cell Line, Tumor; Humans; MAP Kinase Signaling System; Melanoma; Melanoma, Cutaneous Malignant; Mitogen-Activated Protein Kinase Kinases; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrroles; Skin Neoplasms | 2022 |
War against NRAS-Mutant Melanoma Using Targeted Therapies Remains Challenging.
Topics: Aminopyridines; Benzimidazoles; GTP Phosphohydrolases; Humans; Melanoma; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Purines | 2022 |
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer.
Topics: Aminopyridines; Animals; Melanoma; Mice; Programmed Cell Death 1 Receptor; Purines | 2023 |
Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Melanoma; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinases; Morpholines; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Signal Transduction; Skin Neoplasms; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma.
Topics: Aminopyridines; Animals; Cell Line, Tumor; Cell Proliferation; Macrophages; Male; Melanoma; Mice, Inbred C57BL; Proteins; Proto-Oncogene Proteins B-raf; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Skin Neoplasms; Treatment Outcome | 2020 |
E2F1/IGF-1R Loop Contributes to BRAF Inhibitor Resistance in Melanoma.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cell Line, Tumor; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Feedback, Physiological; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hydroxyquinolines; Melanoma; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptor, IGF Type 1; Skin; Skin Neoplasms | 2020 |
The Specific IKKε/TBK1 Inhibitor Amlexanox Suppresses Human Melanoma by the Inhibition of Autophagy, NF-κB and MAP Kinase Pathways.
Topics: Aminopyridines; Animals; Autophagy; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; I-kappa B Kinase; Melanoma; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; NF-kappa B; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2020 |
Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
Topics: Aminopyridines; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dipeptides; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Melanoma; Melanoma, Cutaneous Malignant; Mutagenesis, Site-Directed; para-Aminobenzoates; Phosphorylation; Piperazines; Protein Binding; Protein Phosphatase 2C; Protein Stability; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Skin Neoplasms; Tumor Suppressor Protein p53 | 2018 |
Long-term characterization of activated microglia/macrophages facilitating the development of experimental brain metastasis through intravital microscopic imaging.
Topics: Aminopyridines; Animals; Brain; Brain Neoplasms; Cell Line, Tumor; CX3C Chemokine Receptor 1; Disease Models, Animal; Functional Laterality; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Intravital Microscopy; Macrophages; Matrix Metalloproteinase 3; Melanoma; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Pyrroles; Time Factors; Zonula Occludens-1 Protein | 2019 |
A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600
Topics: Aminopyridines; Disease Progression; Humans; Melanoma; Morpholines; Mutation; Proto-Oncogene Proteins B-raf; Vemurafenib | 2019 |
Drug combo shows promise in NRAS-mutant melanoma.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Proliferation; GTP Phosphohydrolases; Melanoma; Membrane Proteins; Mutation; Purines | 2014 |
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Imidazoles; Indoles; Melanoma; Mice; Microphthalmia-Associated Transcription Factor; Oximes; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidines; Pyrimidinones; Receptor Protein-Tyrosine Kinases; Signal Transduction; Skin Neoplasms; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2014 |
Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model.
Topics: Aminopyridines; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Antigens, Ly; CD11b Antigen; Disease Models, Animal; Female; Flow Cytometry; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Myeloid Cells; Neovascularization, Pathologic; Receptor, Adenosine A2B; Skin Neoplasms; T-Lymphocytes; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2015 |
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
Topics: Aminopyridines; Animals; Antibodies; Cell Line, Tumor; CTLA-4 Antigen; Drug Resistance, Neoplasm; Drug Synergism; Humans; Immunotherapy; Melanoma; Mice; Morpholines; Programmed Cell Death 1 Receptor; PTEN Phosphohydrolase; T-Lymphocytes | 2016 |
The protein kinase IKKepsilon contributes to tumour growth and tumour pain in a melanoma model.
Topics: Aminopyridines; Animals; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Humans; I-kappa B Kinase; Melanocytes; Melanoma; Melanoma, Experimental; Mice, Inbred C57BL; Mice, Knockout; Pain; Skin Neoplasms | 2016 |
Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Cell Line, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Indoles; Melanoma; Mice; Models, Biological; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2016 |
Dimethylaminopyridine derivatives of lupane triterpenoids are potent disruptors of mitochondrial structure and function.
Topics: Aminopyridines; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Proliferation; Humans; Melanoma; Mitochondria; Mitochondrial Membranes; Triterpenes | 2010 |
Stimulation of TNF-alpha production by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) - a novel immunomodulator with potential application in tumour immunotherapy.
Topics: Adamantane; Aminopyridines; Animals; Female; Humans; Melanoma; Mice; NF-kappa B; Ovarian Neoplasms; RNA, Messenger; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |